Đang chuẩn bị liên kết để tải về tài liệu:
Therapy - related acute myeloid leukemia (t - AML) following chemotherapy for non - Hodgkin’s lymphoma

Không đóng trình duyệt đến khi xuất hiện nút TẢI XUỐNG

The patient, a 22-year-old female, was diagnosed with diffuse large B-cell lymphoma (an aggressive non-Hodgkin’s lymphoma). The patient had completed 6 cycles of R-CHOP (from March 2018 to July 2018). After that, the patient was re-examined regularly monthly (manifested with moderate and hypochromic anemia, bone marrow aspiration was negative for malignancy). In November 2019, the complete blood cell (CBC) findings were as follows: White blood cell (WBC) count 81 x109 /liter, neutrophils 7%, lymphocytes 22%, monocytes 2%, blasts 69%; red blood cell count 2.6 x 106 /ml, hemoglobin 7.8 g/dl, platelet count 192.000. |

TÀI LIỆU LIÊN QUAN

Low level laser therapy (Photobiomodulation therapy) for breast cancer-related lymphedema: A systematic review

Nutrition therapy with high intensity interval training to improve prostate cancer-related fatigue in men on androgen deprivation therapy: A study protocol

Clinical decision-making and health-related quality of life during first-line and maintenance therapy in patients with advanced non-small cell lung cancer (NSCLC): Findings from a real-world setting

Resilience and health-related quality of life in patients with pulmonary diseases receiving ambulatory oxygen therapy

NEOnatal Central-venous Line Observational study on Thrombosis (NEOCLOT): Evaluation of a national guideline on management of neonatal catheter-related thrombosis

Therapy - related acute myeloid leukemia (t - AML) following chemotherapy for non - Hodgkin’s lymphoma

Yoga intervention and reminder e-mails for reducing cancer-related fatigue - a study protocol of a randomized controlled trial

Health-related quality of life (HRQOL) and its associated factors in children with Type 1 Diabetes Mellitus (T1DM)

Utilization of antihypertensive drugs in obesity-related hypertension: A retrospective observational study in a cohort of patients from Southern Italy

Health-related quality of life in patients receiving first-line eribulin mesylate with or without trastuzumab for locally recurrent or metastatic breast cancer
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.